Targeted therapies for cancer
US11186875B2 · kind B2 · utility
2Cited by
0References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 13, 2016 |
| Grant date | Nov 30, 2021 |
| Priority date | — |
| Expiry date | Jun 13, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7028
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Various embodiments provide compositions and methods for detecting cancers containing an NRG1 fusion event and treating a patient with a therapeutic agent that is targeted to the NRG1 fusion. Exemplary compositions for treating cancers containing the NRG1 fusion may comprise therapeutic agents inhibiting Epidermal Growth Factor Receptor and/or ERBB2 such as cetuximab, panitumumab, Sym004, MM-151, mAb 806, mAb 528, MEHD794A, gefitinib, erlotinib, lapatinib, afatinib, PD153035, AG1478, trastuzumab, and pertuzumab. In some embodiments, the therapeutic agent may be a combination of trastuzumab, and pertuzumab.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.